LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

Home・Akciju saraksts・MannKind Corp

MannKind Corp

Slēgts

SektorsVeselības aprūpe

3.35 -2.05

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

3.3

Max

3.52

Galvenie mērījumi
By Trading Economics
Ienākumi	-671K -17M
Pārdošana	-22M 90M
P/E Sektora vidējais	140.5 49.888
EPS	-0.02
Peļņas marža	-18.431
Darbinieki	591
EBITDA	5.9M 3.4M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+137.61% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 5. aug.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	223M 1.1B
Iepriekšējā atvēršanas cena	5.4
Iepriekšējā slēgšanas cena	3.35

Ziņu noskaņojums

By Acuity

60%

40%

270 / 344 Rangs Healthcare

MannKind Corp Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 2. jūn. 20:30 UTC

Peļņas

Palo Alto Networks 3Q Revenue Rises as Customers Beef Up Cyber Defenses

2026. g. 2. jūn. 23:58 UTC

Tirgus saruna

Australia's Consumer Sector Expected to Be Stung by Housing Downturn -- Market Talk

2026. g. 2. jūn. 23:46 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 2. jūn. 23:46 UTC

Tirgus saruna

Nikkei May Rise as AI Demand Hopes Continue -- Market Talk

2026. g. 2. jūn. 23:41 UTC

Tirgus saruna

Oil Rises Amid Signs of U.S.-Iran Peace Talks Stalling -- Market Talk

2026. g. 2. jūn. 23:01 UTC

Iegādes, apvienošanās, pārņemšana

ACCC Says Owner of Metro Petroleum Brand to Buy the 41 Sites

2026. g. 2. jūn. 23:01 UTC

Iegādes, apvienošanās, pārņemšana

ACCC Says Ampol Must Sell 41 Retail Fuel Sites to an Approved Purchaser

2026. g. 2. jūn. 23:00 UTC

Iegādes, apvienošanās, pārņemšana

Australia's Competition Regulator Approves Ampol's Purchase of EG Australia With Conditions

2026. g. 2. jūn. 22:57 UTC

Tirgus saruna

Australian Dollar Could Fall Following 1Q GDP Data -- Market Talk

2026. g. 2. jūn. 22:50 UTC

Tirgus saruna

Ulta Beauty Says TikTok Shop Will Provide 'Halo' Effect -- Market Talk

2026. g. 2. jūn. 21:07 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 2. jūn. 21:07 UTC

Tirgus saruna

Tokenized Assets Need Access to Digital-Finance Plumbing -- Market Talk

2026. g. 2. jūn. 21:00 UTC

Peļņas

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2026. g. 2. jūn. 20:50 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2026. g. 2. jūn. 20:46 UTC

Peļņas

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2026. g. 2. jūn. 20:38 UTC

Peļņas

GitLab Stock Rises as the Software Company Raises Guidance on AI Business Momentum -- Barrons.com

2026. g. 2. jūn. 20:21 UTC

Peļņas

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2026. g. 2. jūn. 20:12 UTC

Peļņas

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2026. g. 2. jūn. 20:05 UTC

Peļņas

Palo Alto Networks 3Q Product Rev $594M

2026. g. 2. jūn. 20:05 UTC

Peļņas

Palo Alto Networks Sees FY26 Next-Generation Security ARR $8.9B-$8.95B

2026. g. 2. jūn. 20:05 UTC

Peļņas

Palo Alto Networks Raises FY26 View To Adj EPS $3.77-Adj EPS $3.79 >PANW

2026. g. 2. jūn. 20:05 UTC

Peļņas

Palo Alto Networks 3Q Subscription and Support Rev $2.41B

2026. g. 2. jūn. 20:05 UTC

Peļņas

Palo Alto Networks Sees FY26 Remaining Performance Obligation $20.9B-$21B

2026. g. 2. jūn. 20:05 UTC

Peļņas

Palo Alto Networks Sees 4Q Rev $3.345B-$3.355B >PANW

2026. g. 2. jūn. 20:05 UTC

Peļņas

Palo Alto Networks Sees 4Q Adj EPS 96c-Adj EPS 98c >PANW

2026. g. 2. jūn. 20:05 UTC

Peļņas

Palo Alto Networks on Track to Achieve 40% Adj Free Cash Flow Margin in FY28

2026. g. 2. jūn. 20:05 UTC

Peļņas

Palo Alto Networks Raises FY26 View To Rev $11.415B-$11.425B >PANW

2026. g. 2. jūn. 20:05 UTC

Peļņas

Palo Alto Networks 3Q Remaining Performance Obligation $18.4B

2026. g. 2. jūn. 20:05 UTC

Peļņas

Palo Alto Networks 3Q Adj EPS 85c >PANW

2026. g. 2. jūn. 20:05 UTC

Peļņas

Palo Alto Networks 3Q Loss $177M >PANW

Salīdzinājums

Cenas izmaiņa

MannKind Corp Prognoze

Cenas mērķis

By TipRanks

137.61% augšup

Prognoze 12 mēnešiem

Vidējais 8.15 USD 137.61%

Augstākais 11 USD

Zemākais 4.75 USD

Pamatojoties uz 6 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi MannKind Corp — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

6 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 6 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam MannKind Corp — pēdējo 3 mēnešu laikā.

Noskaņojums

By Acuity

270 / 344 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par MannKind Corp

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.